Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant advancement for cancer treatment, Gilead Sciences and Arcus Biosciences are conducting a Phase 3 study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations. The study aims to compare the overall survival rates of patients receiving zimberelimab and domvanalimab in combination with chemotherapy against those receiving pembrolizumab with chemotherapy.
The interventions being tested include the experimental drugs zimberelimab and domvanalimab, both administered intravenously, alongside standard chemotherapy agents like carboplatin and cisplatin. The goal is to enhance treatment efficacy for patients with untreated metastatic non-small cell lung cancer.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment outcomes. It seeks to determine the effectiveness of the new drug combination in improving patient survival rates.
The study began on October 12, 2022, with an estimated primary completion date yet to be announced. The last update was submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact Gilead Sciences and Arcus Biosciences’ market positions, potentially boosting their stock performance if results are favorable. This development is particularly relevant in the competitive oncology market, where innovation is key to gaining a competitive edge.
The study is currently recruiting, with further details available on the ClinicalTrials portal.